While the promoter methylation of tumor suppressor APC was the most common in CMs (6/9; 67%) compared to cutaneous (7/25; 28%) and other mucosal (8/63; 13%) melanomas, the promoter methylation of tumor suppressor CDKN2A was commonly present in both CMs (4/9; 44%) and cutaneous melanomas (9/25; 36%) but less commonly in other mucosal melanomas (6/63; 10%). This evidence concerns the gene CDKN2A and melanoma.